Association between the Stin2 VNTR polymorphism of the Serotonin transporter gene and treatment outcome in alcohol-dependent patients

Alcohol and Alcoholism

Volumn 43, Issue 5, 2008, Pages 516-522

  Florez, Gerardo ^b   Saiz, Pilar ^a   Garcia Portilla, Paz ^a   Álvarez, Sandra ^b   Nogueíras, Luis ^b   Morales, Blanca ^c   Alvarez, Victoria ^c   Coto, Eliecer ^c   Bobes, Julio ^a  

^a UNIVERSITY OF OVIEDO   (Spain)

^b Unidad Asistencial As Burgas   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE TRANSPORTER; NALTREXONE; PROTEIN SLC6A3; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; TOPIRAMATE;

ADULT; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DISABILITY; DOSE RESPONSE; DRINKING BEHAVIOR; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; FEMALE; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; VARIABLE NUMBER OF TANDEM REPEAT; WITHDRAWAL SYNDROME;

ALCOHOLISM; CHI-SQUARE DISTRIBUTION; FEMALE; FRUCTOSE; GENOTYPE; HAPLOTYPES; HUMANS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; NALTREXONE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; QUALITY OF LIFE; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TREATMENT OUTCOME;

EID: 51749120304     PISSN: 07350414     EISSN: 14643502     Source Type: Journal    
DOI: 10.1093/alcalc/agn048     Document Type: Article

References (77)

1. Addolorato G, Abenavoli L, Leggio L et al. (2005a) How many cravings? Pharmacological aspects of craving treatment in alcohol addiction: A review. Neuropsychobiology 51:59-66.
2. Addolorato G, Leggio L, Abenavoli L et al. (2005b) Neurobiochemical and clinical aspects of craving in alcohol addiction: A review. Addict Behav 30:1209-24.
3. Allen JP, Litten RZ. (2001) The role of laboratory tests in alcoholism treatment. J Subst Abuse Treat 20:81-5.
4. Allen JP, Litten RZ, Strid N et al. (2001) The role of biomarkers in alcoholism medication trials. Alcohol Clin Exp Res 25 1119-25.
5. Anton RF, Moak DH, Latham P. (1995) The obsessive compulsive drinking scale: A self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res 19:92-9.
6. Anton RF, O'Malley SS, Ciraulo DA et al. (2006) COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence - the COMBINE study: A randomized controlled trial. JAMA 295:2003-17.
7. Arinami T, Gao M, Hamaguchi H et al. (1997) A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 6:577-82.
8. Arranz MJ, Munro J, Birkett J et al. (2000) Pharmacogenetic prediction of clozapine response. Lancet 355:1615-16.
9. Babor TF, Longabaugh R, Zweben A et al. (1994) Issues in the definition and measurement of drinking outcomes in alcoholism treatment research. J Stud Alcohol 12:101-11.
10. Bleich S, Bönsch D, Rauh J et al. (2007) Association of the long allele of the 5-HTTLPR polymorphism with compulsive craving in alcohol dependence. Alcohol Alcohol 42:509-12.
11. Bowirrat A, Oscar-Berman M. (2005) Relationship between dopaminergic neurotransmission, alcoholism, and reward deficiency syndrome. Am J Med Genet (Part B: Neuropsychiatr Genet) 132:29-37.
12. Bray NJ, Buckland PR, Hall H et al. (2004) The serotonin-2A receptor gene locus does not contain common polymorphism affecting mRNA levels in adult brain. Mol Psychiatry 9:109-14.
13. Chen WJ, Chen CH, Huang J et al. (2001) Genetic polymorphisms of the promoter region of dopamine D2 receptor and dopamine transporter genes and alcoholism among four aboriginal groups and Han Chinese in Taiwan. Psychiatr Genet 11:187-95.
14. Ciccocioppo R. (1999) The role of serotonin in craving: From basic research to human studies. Alcohol Alcohol 34:244-53.
15. Cisler RA, Zweben A. (1999) Development of a composite measure for assessing alcohol treatment outcome: Operationalization and validation. Alcohol Clin Exp Res 23:263-71.
16. Curtis D, Knight J. (2003) Genecounting Program. http://www.mds.qmul.ac.uk/statgen/dcurtis.html (8 November 2005, date last accessed).
17. Dick DM, Rose RJ, Kaprio J. (2006) The next challenge for psychiatric genetics: Characterizing the risk associated with identified genes. Ann Clin Psychiatry 18:223-31.
18. Dick DM, Plunkett J, Hamlin D et al. (2007) Association analyses of the serotonin transporter gene with lifetime depression and alcohol dependence in the Collaborative Study on the Genetics of Alcoholism (COGA) sample. Psychiatr Genet 17:35-8.
19. Edenberg HJ, Foround T. (2006) The genetics of alcoholism: Identifying specific genes through family studies. Addict Biol 11:386-96.
20. EuroQoL Group. (1990) EuroQoL - a new facility for the measurement of health-related quality of life. Health Policy 16:199-208.
21. Fagerström KO. (1978) Measuring degrees of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav 3:235-41.
22. Fehr C, Schleicher A, Szegedi A et al. (2001) Serotonergic polymorphisms in patients suffering from alcoholism, anxiety disorders and narcolepsy. Prog Neuro-Psychopharmacol Biol Psychiatry 25 965-982.
23. Feinn R, Nellissery M, Kranzler HR. (2005) Meta-analysis of the association of a functional serotonin transporter promoter polymorphism with alcohol dependence. Am J Medical Genet (Part B: Neuropsychiatr Genet) 133B:79-84.
24. Fiskerstrand CE, Lovejoy EA, Quinn JP. (1999) An intronic polymorphic domain often associated with susceptibility to affective disorders has allele dependent differential enhancer activity in embryonic stem cells. FEBS Lett 458:171-4.
25. Franke P, Schwab SG, Knapp M et al. (1999) DAT1 gene polymorphism in alcoholism: A family-based association study. Biol Psychiatry 45:652-4.
26. Hariri AR, Drabant EM, Munoz KE et al. (2005) A susceptibility gene for affective disorders and the response of the human amygdala. Arch Gen Psychiatry 62:146-152.
27. Heinz A, Sander T, Harms H et al. (1996) Lack of allelic association of Dopamine D1 and D2 (TaqIA) receptor gene polymorphisms with reduced dopaminergic sensitivity to alcoholism. Alcohol Clin Exp Res 20:1109-13.
28. Heinz A, Jones DW, Mazzanti C et al. (2000) A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity. Biol Psychiatry 47:643-9.
29. Hesselbrock V, Higuchi S, Soyka M. (2005) Recent developments in the genetics of alcohol-related phenotypes. Alcohol Clin Exp Res 29 1321-4.
30. Hill EM, Stoltenberg SE, Bullard KH et al. (2002) Antisocial alcoholism and serotonin-related polymorphisms: Association tests. Psychiatr Genet 12:143-53.
31. Hranilovic D, Stefulj J, Schwab S et al. (2004) Serotonin transporter promoter and intron 2 polymorphisms: Relationship between allelic variants and gene expression. Biol Psychiatry 55 1090-4.
32. Janca A, Kastrup M, Katschnig H et al. (1996) The World Health Organization Short Disability Assessment Schedule (WHO DAS-S): A tool for the assessment of difficulties in selected areas of functioning of patients with mental disorders. Soc Psychiatry Psychiatr Epidemiol 31:349-54.
33. Johnson BA, Ait-Daoud N, Bowden CL et al. (2003) Oral topiramate for treatment of alcohol dependence: A randomised controlled trial. Lancet 361:1677-85.
34. Johnson BA, Rosenthal N, Capece JA et al. (2007) Topiramate for treating alcohol dependence: A randomized controlled trial. JAMA 298:1641-51.
35. Johnson BA, Javors MA, Roache JD et al. (2008) Can serotonin transporter genotype predict serotonergic function, chronicity, and severity of drinking? Pro Neuro-Psychopharmacol Biol Psychiatry 32:209-16.
36. Kaprio J, Koskenvuo M, Langinvainio H et al. (1987) Genetic influences on use and abuse of alcohol: A study of 5638 adult Finnish twin brothers. Alcohol Clin Exp Res 11:349-56.
37. Kendler KS, Jacobson KC, Prescott CA et al. (2003) Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins. Am J Psychiatry 160:687-95
38. Kessler RC, Berglund P, Demler O et al. (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62 593-602.
39. Kiefer F, Helwig H, Tarnaske T et al. (2005) Pharmacological relapse prevention of alcoholism: Clinical predictors of outcome. Eur Addict Res 11:83-91.
40. Kiefer F, Jiménez-Arriero MA, Klein O et al. (2008) Cloninger's typology and treatment outcome in alcohol-dependent subjects during pharmacotherapy with naltrexone. Addict Biol 13:124-9.
41. Kokkevi A, Hartgers C. (1995) European adaptation of a multidimensional assessment instrument for drug and alcohol dependence. Eur Addict Res 1:208-10.
42. Konishi T, Luo HR, Calvillo M et al. (2004) ADH1B*1, ADH1C*2, DRD2 (-141 c Ins), and 5-HTTLPR are associated with alcoholism in Mexican American men living in Los Angeles. Alcohol 28 1145-52.
43. Kouzmenko AP, Scaffidi A, Pereira AM et al. (1999) No correlation between A(-1438)G polymorphism in 5-HT2A receptor gene promoter and the density of frontal cortical 5-HT2A receptors in schizophrenia. Hum Hered 49:103-5.
44. Kusumi I, Suzuki K, Sasaki Y et al. (2002) Serotonin 5-HT(2A) receptor gene polymorphism, 5-HT(2A) receptor function and personality traits in healthy subjects: A negative study. J Affect Disord 68:235-41.
45. Lannfelt L, Sokoloff P, Martres MP et al. (1992) Amino-acid substitution in the dopamine D3 receptor as a useful polymorphism for investigating psychiatric disorders. Psychiatr Genet 2 249-56.
46. Loranger AW, Sartorius N, Andreoli P et al. (1994) The international personality disorder examination. Arch Gen Psychiatry 51:215-24.
47. Lovejoy EA, Scott AC, Fiskerstrand CE et al. (2003) The serotonin transporter intronic VNTR enhancer correlated with a predisposition to affective disorders has distinct regulatory elements within the domain based on the primary DNA sequence of the repeat unit. Eur J Neurosci 17:417-20.
48. Lundstrom K, Turpin MP. (1996) Proposed schizophrenia-related gene polymorphism: Expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem Biophys Res Commun 225:1068-72.
49. Luo HR, Hou ZF, Wu J et al. (2005) Evolution of the DRD2 gene haplotype and its association with alcoholism in Mexican Americans. Alcohol 36:117-25.
50. MacKenzie A, Quinn J. (1999) A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo. Proc Natl Acad Sci USA 96:15251-5.
51. Martinez-Barrondo S, Saiz PA, Morales B et al. (2005) Serotonin gene polymorphisms in patients with panic disorder. Actas Esp Psiqiatr 33:210-6.
52. Mata I, Arranz MJ, Patino A et al. (2004) Serotonergic polymorphisms and psychotic disorders in populations from North Spain. Am J Med Genet (Part B: Neuropsychiatr Genet) 126:88-94.
53. McGue M. (1999) The behavioral genetics of alcoholism. Curr Dir Psychol Sci 8:109-15.
54. Miller SA, Dykes DD, Polesky HF. (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215.
55. Mulert C, Juckel G, Giegling I et al. (2006) A Ser9Gly polymorphism in the dopamine D3 receptor gene (DRD3) and event-related P300 potentials. Neuropsychopharmacology 31:1335-44.
56. Parsons MJ, D'Souza UM, Arranz MJ et al. (2004) The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. Biol Psychiatry 56:406-10.
57. Preuss UW, Koller G, Bondy B et al. (2001) Impulsive traits and 5-HT2A receptor promoter polymorphism in alcohol dependents: Possible association but no influence of personality disorders. Neuropsychobiology 43:186-91.
58. Rollnick S, Heather N, Gold R et al. (1992) Development of a short 'readiness to change' questionnaire for use in brief, opportunistic interventions among excessive drinkers. Br J Addict 87 743-54.
59. Saiz PA, García-Portilla MP, Arango C et al. (2007) Association study of serotonin 2A receptor (5-HT2A) and serotonin transporter (5-HTT) gene polymorphisms with schizophrenia. Prog NeuroPsychopharmacol Biol Psychiatry 31:741-5.
60. Samochowiec J, Kucharska-Mazur J, Grzywacz A et al. (2006) Family-based and case-control study of DRD2, DAT, 5HTT, COMT genes polymorphisms in alcohol dependence. Neurosci Lett 410, 1-5.
61. Sander T, Ladehoff M, Samochowiec J et al. (1999) Lack of an allelic association between polymorphisms of the dopamine D2 receptor gene and alcohol dependence in the German population. Alcohol Clin Exp Res 23:578-81.
62. 9 allele of the dopamine transporter gene. Am J Psychiatry 155:474-8.
63. Spurlock G, Heils A, Holmans P et al. (1998) A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter. Mol Psychiatry 3:42-9.
64. Srisurapanont M, Jarusuraisin N. (2005) Naltrexone for the treatment of alcoholism: A meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 8:267-80.
65. Stout RL. (2003) Methodological and statistical considerations in measuring alcohol treatment effects. Alcohol Clin Exp Res 27 1686-91.
66. Tupala E, Tiihonen J. (2004) Dopamine and alcoholism: Neurobiological basis of ethanol abuse. Prog Neuro-Psychopharmacol Biol Psychiatry 28:1221-47.
67. Vaillant GE. (2003) A 60-year follow-up of alcoholic men. Addiction 98:1043-51.
68. Vandenbergh DJ, Persico AM, Hawkins AL et al. (1992) Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 14:1104-06.
69. Van Dyck ChH, Malison RT, Jacobsen LK et al. (2005) Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J Nucl Med 46:745-51.
70. VanNess SH, Owens MJ, Kilts CD. (2005) The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density. BMC Genet 6:55-66.
71. Volkow ND, Fowler JS, Wang GJ. (2004) The addicted human brain viewed in the light of imaging studies: Brain circuits and treatment strategies. Neuropharmacology 47:3-13.
72. Wiesbeck GA, Weijers HG, Wodarz N et al. (2003) Dopamine D2 (DAD2) and dopamine D3 (DAD3) receptor gene polymorphisms and treatment outcome in alcohol dependence. J Neural Transm 110:813-20.
73. Wiesbeck GA, Dursteler-MacFarland KM, Wurst FM et al. (2006) No association of dopamine receptor sensitivity in vivo with genetic predisposition for alcoholism and DRD2/DRD3 gene polymorphisms in alcohol dependence. Addict Biol 11:72-5.
74. Wojnar M, Brower KJ, Jakubczyk A et al. (2006) Influence of impulsivity, suicidality and serotonin genes on treatment outcomes in alcohol dependence. Psychiatr Pol 40:985-94.
75. World Medical Association. (1989) Declaration of Helsinki, recommendations guiding physicians in biomedical research involving human subjects. Amended by the 41st World Medical Assembly, Hong Kong.
76. World Health Organization. (1992) ICD-10, 10th Revision of the International Classification of Diseases. World Health Organization, Madrid.
77. Worst TJ, Vrana KE. (2005) Alcohol and gene expression in the central nervous system. Alcohol Alcohol 40:63-75.